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Abstract
Background: Debate about medical cannabis legalization are typically informed by three beliefs: (1) cannabis has
medical effects, (2) medical cannabis is addictive and (3) medical cannabis legalization leads to increased used of
cannabis for recreational purposes (spillover effects). We examined how strongly these beliefs are associated with
public support for medical cannabis legalization and whether this association differs across divergent medical
cannabis policy regimes.
Methods: Robust regression analysis was used to analyse data derived from two nationally representative samples
of adults participating in comparable cross-sectional online surveys in one country where medical cannabis
smoking is illegal (Norway, n = 2175, 51 % male) and in one country where medical cannabis smoking is legal
(Israel, n = 648, 49 % male).
Results: The belief that cannabis has medical benefits was more strongly related to support for medical cannabis
legalization than were beliefs about addiction and spillover effects. While the support for medical cannabis
legalization was stronger in Israel than in Norway (78 vs. 51 %, p < 0.01), the belief variables had, in general, more
impact on the policy stand in Norway.
Conclusion: The belief that cannabis has medical benefits is particularly salient for support for medical cannabis
legalization. It is possible that the recent surge in evidence supporting the medical benefits of cannabis will
increase the belief about medical benefits of cannabis in the general population which may in turn increase public
support for medical cannabis legalization. Results also suggest that once medical cannabis is legalized, factors
beyond cannabis-specific beliefs will increasingly influence medical cannabis legalization support. These conclusions
are, however, only suggestive as the current study is based on cross-sectional data. Hopefully, future research will
be able to capitalize on changes in medical cannabis policies and conduct longitudinal studies that enable an
examination of the causal relation between public opinion and medical cannabis policy changes.
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Introduction
Medical cannabis policies are currently undergoing rapid
changes, with increasingly more jurisdictions around the
world legalizing medical cannabis for certain groups of
patients. These include 23 states in the USA [1] and
countries like Israel, Canada and the Netherlands [2].
Other nations are currently considering the same policy
change, e.g. New Zealand and Australia [1, 3]. At the
same time, there are many more countries where med-
ical cannabis legalization is absent from the current pol-
icy agenda and public debates.
Although very little peer-reviewed scientific literature
exists on public opinion towards medical cannabis pol-
icy, it has been noted that public opinion has played an
important role in affecting medical cannabis policy for-
mation, modification and support [1]. To understand the
dynamics of medical cannabis policies and to begin to
create a framework for forecasting future developments
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in this policy area, there is a need to examine public
support for medical cannabis legalization. Furthermore,
as public support can influence and at the same time be
influenced by national policies, it is imperative to study
public support across different medical cannabis policy
regimes, as this enables an investigation of whether dif-
ferences in public opinion reflect variation in medical
cannabis policies. In this paper, we examine the extent
to which beliefs, intrinsic to claims frequently made in
the medical cannabis debate, relate to support for med-
ical cannabis legalization and whether the relationships
differ across divergent medical cannabis policy regimes.
There are three common beliefs that are frequently de-
liberated in public and policy debates of medical canna-
bis legalization. The first belief is about the medical
benefits on cannabis, and many question the therapeutic
value of cannabis in clinical practice [1]. Proponents
of medical cannabis highlight the continuing emer-
gence of evidence that demonstrates the therapeutic
value of cannabis in treating a variety of disease-
related problems [4, 5].
Secondly, medical cannabis legalization debates have
revolved around topics of addiction and abuse. Official
policies mandated by the 1961 UN Convention highlight
the abuse potential of cannabis, and there is a vast re-
search literature that identifies harmful effects of canna-
bis use [6]. While opponents of medical cannabis have
highlighted the abuse potential, proponents have noted
that cannabis is far less addictive and harmful than other
prescription medicines [7, 8].
Thirdly, spillover effects are often discussed in debates
about cannabis legalization, including the concern that
medical cannabis legalization may lead to increased rec-
reational cannabis use. There are various ways in which
this is thought to occur. It has, for instance, been argued
that medical cannabis legalization leads to diversion of
medical cannabis to the black market [9]. Others have
noted that medical cannabis legalization leads to in-
creased recreational cannabis use because it sends “the
wrong messages to the public” that cannabis for recre-
ational purposes is acceptable and that there is little risk
to the user and society [9–11]. This is closely connected
with the fact that medical cannabis is typically smoked,
which raises the concern that medical cannabis
legalization blurs the boundaries between cannabis for
therapeutic purposes and cannabis for recreational
purposes [12].
Study objectives
The aims of our study were twofold. Firstly, we exam-
ined the extent to which beliefs underlying the medical
cannabis debate relate to support for medical cannabis
legalization. On the one hand, one may expect that be-
lieving that cannabis has medical benefits will be
associated with support for medical cannabis legalization
and that beliefs in the negative effects of medical canna-
bis (e.g. addiction and spillover effects) will be associated
with opposition to medical cannabis legalization. How-
ever, the converse is also theoretically plausible. It is pos-
sible that cannabis is generally accepted as a medicine,
which in turn goes hand in hand with the acceptance
that a certain level of unintended negative effects (e.g.
addiction and spillover effects) is inevitable. Seen from
this perspective, it is possible that addiction and spillover
beliefs are positively rather than negatively related to
medical cannabis legalization.
Secondly, our study aimed to examine if and how sup-
port for medical cannabis legalization differs across di-
vergent medical cannabis policy regimes. Ideally, we
would have liked to compare data pre- and post-policy
changes across different legal jurisdictions within a
country. However, such “natural experiment” data are
rare in the social sciences and are not available here.
Thus, we chose the next best option which was to com-
pare individual level data collected in two countries
(Israel and Norway) that have many similarities but
which differ with regard to medical cannabis policies.
Methods
We used a cross-national data set to compare public
opinion towards medical cannabis legalization between
Norway and Israel. Respondents read and agreed to an
informed consent form before filling in the survey. In
Norway, a nationally representative sample (n = 2175) of
the adult (aged 18+) population was recruited for a Nor-
wegian language online survey. In Israel, a nationally
representative sample (n = 648) of the adult (aged 18+)
Jewish population was recruited for a Hebrew language
online survey. The two national surveys included identi-
cal questions about cannabis policy attitudes and beliefs,
cannabis use, demographics and other background fac-
tors. IRB approval was granted by the Social Welfare
and Health Sciences Department at the University of
Haifa (nr. 289/13).
Dependent variable
Respondents were asked to assess the extent to which
they agreed that cannabis use should be legal for pa-
tients if a physician recommends it. Response categories
were presented on a Likert scale indicating the range
from strongly disagree (=1) to strongly agree (=5). There
was also a “don’t know” category which was combined
with the Likert scale midpoint “neither agree nor dis-
agree” category.
Covariates
Previous research has found that gender, education, age,
alcohol and drug use experiences relate to drug policy
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support [13–15]. Therefore, the following control var-
iables were coded for inclusion in the analysis: gender
(0 = female, 1 = male), dummy age categories (18–29,
30–44, 45–59, 60+), dummy variables for highest
completed education level (primary, secondary and
higher education), last year cannabis use (0 = no, 1 = yes)
and last month alcohol use (0 = no, 1 = yes).
Belief variables
The three common beliefs underlying the medical can-
nabis debate were explored. The beliefs that (1) cannabis
has medical benefits and that (2) medical cannabis is ad-
dictive were recorded separately on a 5-point scale ran-
ging from 1 = strongly disagree to 5 = strongly agree.
There was also a “don’t know” category which was com-
bined with the Likert scale midpoint “neither agree nor
disagree” category. To explore the third belief item, we
asked respondents how likely they thought that medical
cannabis legalization led to increased cannabis use for
non-medical purposes. Response categories ranged from
very unlikely (=1) to very likely (=4).
National medical cannabis policy variable
To examine public opinion as a function of medical can-
nabis policy regime, a variable indicating whether respon-
dents were from Norway (=0) or Israel (=1) was coded.
Israel and Norway share important population and
geographic characteristics including relatively small
population sizes (five million in Norway and eight million
in Israel), and both are not members of the European
Union despite being in close proximity to Europe. Fur-
thermore, both countries define cannabis as a schedule 1
drug of abuse, and both enforce criminal prosecution
against personal use and trafficking of cannabis. By inter-
national standards, Israel and Norway have relatively low
cannabis prevalence rates [16–18]. A national representa-
tive survey in Israel showed that 8.9 % of the adult popula-
tion (18–40 years) reported having used cannabis in the
previous year [19]. In Norway, the corresponding last year
cannabis prevalence (16–34 years) was 7.0 % [20].
In contrast to these similarities, Norway and Israel
represent divergent medical cannabis policy regimes
which enable an investigation of the extent to which
medical cannabis policy support relates to actual na-
tional medical cannabis policies. Israel has been running
a medical cannabis program since the late 1990s [21] in
which the use of cannabis is allowed after specialist phy-
sicians’ recommendation and medical cannabis licence
approval. Individual patients obtain medical cannabis li-
cences which specify monthly dosage and medical can-
nabis supplier. Medical cannabis suppliers produce high-
grade medical cannabis that is most commonly adminis-
tered by smoking or vaporizing. In recent years, the rate
of medical cannabis licences granted in Israel has grown
significantly—from just a few hundred in 2007 to an es-
timated 22,000 in 2015 [22]. Medical cannabis has also
been subject to much public and media debate, and
newspaper reports on medical cannabis have tended to
describe cannabis as a prescription drug rather than a
recreational drug [23].
In Norway, medical cannabis in smoked form is not
allowed. In 2012, prescription of Sativex®, a cannabis ex-
tract which is administered orally with an oromucosal
spray, was approved. Potentially, due to the fact that
Sativex® is administered by spray and not smoking, the
prescription of Sativex® has not generated much public
debate or media attention in Norway. The use so far is
limited; by the end of 2013, there were 402 registered
Sativex® patients and the number decreased to 365 pa-
tients in 2014.
Analytical strategy
For descriptive statistics, proportional tests were used to
determine national sample differences on key variables.
Spearman correlations were used to examine the bivari-
ate relation between public support for medical cannabis
legalization and the beliefs commonly underlying the
medical cannabis debate. Public support for medical
cannabis legalization was further examined in multivari-
ate linear regression models. To account for heterogen-
eity and lack of normality, Huber–White sandwich
estimators were used to calculate robust standard errors
[24]. In the first step of the multivariate regression ana-
lysis, we entered only the covariates and the country
variable to examine country differences after control for
background variables. Thereafter, we entered the belief
variables to examine their relation to support for med-
ical cannabis legalization net of background variables.
Lastly, in order to examine the extent to which under-
lying beliefs are differently associated with support for
medical cannabis policy in Israel and in Norway, inter-
action terms between belief variables and nation were
entered one at a time. Marginal effects were calculated
and presented graphically. In order to test the robustness
of results, sensitivity analysis without cannabis users was
conducted. Stata [25] was used for all analyses.
Results
Table 1 presents unadjusted statistics and shows that
there was more support for medical cannabis legalization
in Israel than in Norway (78 % of Israeli respondents
strongly agreed/agreed that medical cannabis should
be legal [mean = 4.1] vs. 53 % of Norwegians [mean = 3.3],
p < 0.001). The national sample distributions across gen-
der and the older age groups (45+) were similar. However,
there were slightly more respondents in the youngest age
group in the Norwegian sample, whereas there were more
respondents in the second youngest age group in the
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Israeli sample. Norwegians were more likely to have sec-
ondary education than Israelis. Norwegians were slightly
more likely to report alcohol use in the previous month
(74 vs. 69 %, p < 0.05), whereas Israelis were more likely
than Norwegians to report cannabis use in the previous
year (13 vs. 5 %, p < 0.001). Compared to Norwegians,
Israelis were more likely to believe that cannabis has
medical benefits (67 vs. 29 %, p < 0.001) and less
likely to believe that medical cannabis is addictive (34
vs. 55 %, p < 0.001). An equal and high proportion of
respondents in both countries endorsed the belief that
medical cannabis legalization will increase recreational
non-medical use (60 % in both countries, p > 0.05).
Correlations between beliefs and support for medical
cannabis legalization are presented separately for Israel
and Norway in Table 2 (upper and lower part of the
table). Support for medical cannabis legalization was
most strongly and positively related with the belief that
cannabis has medical benefits in both countries. How-
ever, while the correlation was strong in the Norwegian
data (rs = .71, p < 0.001), it was relatively weak in the Is-
raeli data (rs = .26, p < 0.001). A stronger belief that med-
ical cannabis was addictive had significantly negative
(albeit weak) association with support for medical canna-
bis legalization support in Norway (rs = −.22, p < 0.001)
and Israel (rs = −.11, p < 0.001). The spillover belief was
negatively related to legalization support in Norway
(rs = −.39, p < 0.001) while the relation was not signifi-
cant in the Israeli sample (rs = −.06, p > 0.05). Results
presented in Table 2 also show that in both countries,
the belief items are significantly but not strongly as-
sociated with each other.
Table 1 Distribution of background and independent and dependent variables in Norway and Israel
Norway (n = 2175) Israel (n = 648) p value for country difference
Strongly agree/agree that medical cannabis should be legal, % (n) 53.2 (1158) 78.4 (508)
[Mean (SD)] [3.3 (0.03)] [4.1 (0.04)] <0.001
Male, % (n) 50.8 (1104) 49.1 (318) 0.342
Age categories
18–29, % (n) 26.4 (576) 22.1 (143) 0.003
30–44, % (n) 23.9 (519) 28.7 (186) 0.010
45–59, % (n) 30.0 (652) 28.9 (187) 0.795
60+, % (n) 19.7 (429) 20.4 (132) 0.416
Education
Primary, % (n) 7.5 (164) 28.1 (182) <0.001
Secondary, % (n) 62.2 (1353) 24.3 (157) <0.001
Higher education, % (n) 30.2 (658) 47.6 (308) <0.001
Behaviour
Last month alcohol use, % (n) 74.3 (1616) 69.1 (448) 0.010
Last year cannabis use, % (n) 5.3 (115) 13.0 (84) <0.001
Beliefs
Strongly agree/agree that cannabis has medical benefits, % (n) 29.2 (635) 66.7 (432) <0.001
Strongly agree/agree that medical cannabis is addictive, % (n) 54.5 (1186) 34.3 (222) <0.001
Very likely/likely that medical cannabis legalization leads to
increased cannabis use, % (n)
60.4 (1313) 60.3 (391) 0.953
p values are based on two-sample tests of proportions








Support for medical cannabis legalization 1.00 0.26** −0.11** −0.06
Cannabis has medical benefits 0.71*** 1.00 −0.34*** 0.27***
Medical cannabis is addictive −0.22*** −0.20*** 1.00 −0.35***
Spillover −0.39*** 0.32*** −0.33*** 1.00
**p < 0.01; ***p < 0.001
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The multivariate regression results presented in model
1 in Table 3 show that education and age were not inde-
pendently associated with support for medical cannabis
legalization (p > 0.05). Males (coeff. = 0.143, p < 0.01) and
those who reported for recent use of alcohol (coeff. =
0.186, p < 0.01) and cannabis use (coeff. = 0.892, p < 0.001)
were relatively supportive of medical cannabis legalization.
Furthermore, the multivariate results confirm that Israelis
are more likely to support medical cannabis legalization
than their Norwegian counterparts (coeff. = 0.712,
p < 0.001).
In model 2, Table 3, the three belief variables were
added to the regression equation. Results show that a
stronger belief that cannabis has medical benefits is as-
sociated with stronger support for medical cannabis
legalization (coeff. = 0.732, p < 0.001), whereas a stronger
belief that medical cannabis legalization will lead to in-
creased non-medical cannabis use is associated with less
support for medical cannabis legalization (coeff. =
−0.236, p < 0.001). Believing that medical cannabis is ad-
dictive was not independently associated with medical
cannabis legalization support (p > 0.05).
The multivariate regression model differed from the
previous model in that it showed that after inclusion of
belief variables, there were no national differences in
support for cannabis legalization (coeff. = 0.054, p >
0.05), and cannabis use was no longer a significant pre-
dictor of support for medical cannabis legalization
(coeff. = −0.087, p > 0.05). To examine this in more
depth, we entered the independent belief variables one
at a time. This showed that national and cannabis use
differences in support for medical cannabis legalization
disappeared when the item about medical effects of can-
nabis was entered into the model. None of the other be-
lief variables had this same influence on results (results
not shown but available upon request).
To examine policy regime differences in the associ-
ation between medical cannabis policy support and
cannabis-related beliefs, interaction terms and marginal
effects were examined. Results presented in model 3 in
Table 3 show that all interactions were statistically sig-
nificant. Figure 1a–c presents the marginal effects for
medical cannabis policy support. In graph 1A, the slope
for Norway is steeper than the slope for Israel, indicating
Table 3 Regression models predicting support for medical cannabis legalization (n = 2803)
Predictors Model 1 Model 2 Model 3
Coeff. Robust S.E. p value Coeff. Robust S.E. p value Coeff. Robust S.E. p value
Demographics
Male 0.143 0.054 0.007 0.114 0.041 0.005
Age (referent: age category 18–29)
Age 30–44 0.100 0.075 0.185 −0.036 0.057 0.529
Age 45–59 0.133 0.073 0.068 0.038 0.055 0.496
Age 60+ −0.152 0.081 0.062 −0.065 0.064 0.303
Education (referent: primary)
Secondary −0.002 0.087 0.979 −0.132 0.074 0.077
Higher education 0.135 0.086 0.118 0.029 0.076 0.702
Behaviour
Last month alcohol use 0.186 0.062 0.003 0.144 0.046 0.002
Last year cannabis use 0.892 0.081 <0.001 0.087 0.072 0.226
National policies
Israel 0.712 0.061 <0.001 0.054 0.061 0.375
Beliefs
Cannabis has medical benefits 0.732 0.018 <0.001
Medical cannabis is addictive 0.016 0.019 0.399




Israel, cannabis has medical benefits −0.625 0.052 <0.001
Israel, medical cannabis is addictive 0.235 0.049 <0.001
Israel, medical cannabis legalization
leads to increased cannabis use
0.553 0.071 <0.001
Coeff. coefficient, S.E. standard errors
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that the belief that cannabis has medical benefits was
more strongly related to medical cannabis policy support
in Norway than it was in Israel. Graph 1B shows that in
Norway, there is no association between the belief that
cannabis is addictive and support for medical cannabis
legalization (indicated by overlapping confidence inter-
vals). In contrast, in Israel, a stronger belief that canna-
bis is addictive was associated with stronger support for
medical cannabis legalization. Graph 1C shows that in
Norway, the greater concern for spillover effects was
associated with less support for medical cannabis
legalization. This contrasted with results for Israel where
the slope was less steep than for Norway, and the rela-
tionship was the opposite; stronger belief in spillover ef-
fects was associated with stronger support for medical
cannabis legalization.
Sensitivity analyses
Although we did not make causal claims when analysing
and interpreting this cross-sectional data set, it may still
be argued that some unobserved variables could influ-
ence both the attitudes towards medical cannabis
legalization (the dependent variable) and cannabis use in
the previous year. These variables could have contami-
nated the results. While we have no means to fully
examine or account for these, a sensitivity analysis was
conducted to test the robustness of the reported results,
where we excluded last year cannabis users (n = 200)
and compared the results to those of the original model
(model 2). Results from the sensitivity analyses show
similar patterns (results not shown but available upon
request); the same variables were statistically significant
and the coefficients stayed roughly the same. Only
secondary education changed from non-significant
(p = 0.077) to significant (p = 0.033) and the coefficient
from 0.13 to 0.15.
We also checked the correlation between last year
cannabis use and the belief variables in case they had
created a collinearity problem. The correlations were























































































































medical cannabis legalization increases non-medical cannabis use
Figure 1 Predicted margins with 95 % CIs for Norway and Israel for support for medical cannabis legalization
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the spillover belief to 0.252 for cannabis use and the
medical benefit belief.
Discussion
The public, political and research interest in medical
cannabis has increased immensely in recent years. A
wave of interest into the structural and physiological
properties of cannabis and a surge of clinical trials has
improved the evidence that cannabis is a promising anti-
emetic and anti-pain medication [4, 5, 26]. However, and
albeit the emergence of promising evidence, the evi-
dence base supporting its efficacy varies substantially
and in general falls short of the standards required for
approval of other drugs by the US Food and Drug
Administration [10, 27–29].
In addition to this emerging, albeit weak, evidence
base, social movements have fought for legal access to
medical cannabis. Public pressure to change medical
cannabis policies has succeeded in many jurisdictions,
yet medical cannabis continues to be controversial be-
cause of the potential detrimental public health effects
[9, 30–33] and the evolving, yet still weak, evidence base
just mentioned. In the midst of these debates and policy
changes, and at a time when much is unknown about
the future of medical cannabis policies and their poten-
tial effects, it is essential to gain a more nuanced under-
standing of the nature, extent and rationale for public
opinion related to medical cannabis policies. Indeed, a
better understanding of public opinion can provide a
framework for an improved understanding of current
and future policy developments.
Our study has examined the relationship between sup-
port for medical cannabis legalization and three beliefs
commonly underlying medical cannabis debates, namely
that (1) cannabis has medical benefits, (2) cannabis is
addictive and (3) medical cannabis legalization leads to
spillover effects. Given the increased attention to spill-
over effects in the scientific literature and in the media
[9], one may expect that the belief about spillover effects
would have been relatively more influential than the
other beliefs examined in this study. However, the bivari-
ate analysis shows that the belief that cannabis has med-
ical benefits is most closely related to support for
medical cannabis legalization, whereas the belief of the
negative effects of medical cannabis use (e.g. addiction
and spillover effects) is less important to public support
for medical cannabis legalization.
These findings are further strengthened by the multi-
variate analysis that showed that the national differences
in support for medical cannabis legalization (78 % in
Israel and 51 % in Norway) were by and large explained
by differences in the beliefs that cannabis has medical
effects and not by the other belief variables. This
strengthens the conclusion that public opinion towards
medical cannabis legalization may be mainly driven by
deliberations related to the medical effects of cannabis,
as opposed to concerns for detrimental public health
effects (spillover and addiction effects).
These findings have particular public health and policy
implications as they suggest that the recent revival of
clinical research and increasing evidence of the medical
benefits of medical cannabis [34–37] may be particularly
influential in forming and increasing support for medical
cannabis legalization. Indeed, this development in basic
and clinical research may fuel the public’s belief that
cannabis has medical effects, which the current study
has shown to be particularly important to public support
for medical cannabis legalization.
It has been noted that medical cannabis policy has
sometimes been developed without a strong public
health agenda [38, 39]. In some jurisdictions, medical
cannabis policies have developed in a manner that serves
for-profit businesses and large-scale commercialization
and marketing of medical cannabis products. One out-
come is that a range of consumables, from lollies, choc-
olate and peanut butter to wine and e-cigarettes
containing THC (the main psychoactive compound in
the cannabis plant), are widely advertised and available
[32]. While the consequences of such trends are yet to
be fully understood, studies have found an increase in
illicit cannabis use in jurisdictions that have commercial-
ized medical cannabis [40, 41]. Studies have also found
an increase in poison centre calls mentioning cannabis
in these jurisdictions, although unintentional digestion
remains low even after medical cannabis legalization
[30, 42, 43]. The observed increase in use and poison
centre calls may be caused by greater availability,
commercialization and unsafe storage of cannabis in
households. However, it is also possible that it is re-
lated to increased willingness to report cannabis use
and unintentional cannabis exposure in an atmos-
phere where medical cannabis is legal [9]. Research
has also found that more than a quarter of adoles-
cents in a Californian school sample were exposed to
advertisement for medical cannabis and that this ex-
posure was associated with greater cannabis use one
year later [32]. The relatively weak relation we found
between concerns for detrimental public health effects
and support for medical cannabis legalization suggests
that there may be limited public support for reversing
medical cannabis policy in response to the variety of
potential unintended consequences.
Another finding of this study is that in Israel, stronger
beliefs regarding addiction and spillover effects are related
to stronger support for medical cannabis legalization.
While this at first seems counterintuitive, it may indicate
the acknowledgement of cannabis simply being another
prescription drug. Indeed, other pharmaceuticals (and
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especially those used for chronic pain and cancer pain
management) are highly addictive and have spillover
effects [44, 45], so negative side effects do not per se imply
that such drugs should not be used in medical practice. In
Norway, however, where cannabis is less likely to be
accepted as a prescription drug, the belief of potential
detrimental effects, such as increased recreational use, is
associated with weakened support for medical cannabis
legalization.
Another possibility is that after years of experience
with a state-supported program providing medical
cannabis to specific groups of patients, Israelis are aware
that such a program is congruent with state policies of
prohibition and control over cannabis use for re-
creational purposes. Thus, it is possible that although
addiction and some spillover effect are acknowledged,
this does not translate into lack of support for medical
cannabis legalization in Israel.
Further, it is worth noting that the belief that cannabis
has medical benefits is a much stronger predictor of
medical cannabis legalization support in Norway than in
Israel. One possible reason for this is that there has been
a “legitimacy-conferring process” [46] in Israel whereby
medical cannabis legalization has earned legitimacy
through expert judgment of authoritative institutions who
are responsible for running the medical cannabis program.
Such a legitimization process is likely to increase support
for medical cannabis legalization in Israel, regardless of
the beliefs Israelis hold towards medical cannabis.
Another explanation is that factors not examined in
this study could be pertinent to support for medical can-
nabis policy support in Israel. For instance, direct experi-
ence has been shown to be important to belief formation
[47]. The fact that Israel has a growing number of med-
ical cannabis patients increases the chances that Israelis
will know someone who uses medical cannabis, and this
may be an important factor for medical cannabis policy
support in Israel which was not captured during our
study. Beliefs will also be influenced by knowledge [47].
Since medical cannabis has been on the media agenda in
Israel much more than in Norway, it is possible that
Israelis are more knowledgeable about the topic and that
this is what determines their support for medical canna-
bis policy. Unfortunately, testing this formally was
beyond the scope of our study.
Limitations
The strength of the study lies in the identical data col-
lection processes and identical questionnaires in two
countries with different medical cannabis policies. The
study does, however, have limitations that must be
considered. Firstly, only two countries were included in
the study. More evidence from different jurisdictions
regarding beliefs and tolerance towards medical cannabis
policies as a function of different policy regimes is
desirable. Furthermore, the study was cross-sectional,
and thus, no causal inferences could be drawn. As more
countries legalize medical cannabis, the opportunity to
conduct longitudinal studies that examine the causal
relation between public opinion and medical cannabis
policy changes will be available. Hopefully, researchers
will be able to capitalize on these changes to develop the
evidence base further.
Lastly, self-reported data on sensitive topics (such as
cannabis use) can be influenced by memory or motiv-
ational biases. Contrary to this, research has shown
that reports of drug use have high reliability and valid-
ity [48, 49]. In particular, web-based reports of canna-
bis use and related issues have been shown to be valid
and reliable [50].
Conclusion
Medical cannabis is an unconventional and highly con-
tested prescription drug. The increasing and sometimes
heated public debates over whether or not medical can-
nabis should be legalized clearly underline this. This
study suggests that public support for medical cannabis
legalization is likely to continue to grow. This conclusion
is based on the observation that the scientific evidence
supporting medical benefits of cannabis seems continu-
ously to grow and also on our finding that the belief in
the medical benefits of cannabis is particularly important
to public support for medical cannabis legalization. Ar-
guments related to public health and the negative effects
of cannabis, on the other hand, have less bearing on
public support for medical cannabis legalization. Contin-
ued research is needed to investigate how public health
considerations can be made more salient in current
medical cannabis policy developments, public opinion
and deliberations.
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